The EU Commission has updated its Q&A on the restriction of Cr(VI) substances to address questions and provide guidance on the upcoming transition from the REACH Authorisation process to a potential Cr(VI) restriction under REACH, following a mandate sent to ECHA in September 2023. The restriction is intended to manage the high workload from Cr(VI) authorisation applications and to control the risks of these potent carcinogens, with ECHA that published its restriction proposal in June 2025. This Q&A document intends to address the most frequently asked questions concerning the Commission’s risk management of Cr(VI) substances under REACH. Companies dealing with Cr(VI) compounds are encouraged to consult the document for more information.
If your question is not answered in the document, send it to
GROW-F1(at)ec.europa.eu.